

| | | | |
|-----|------------------------|---|--|
| | | Interventions: | Biological: BCG vaccine; Biological: CD80 breast cancer vaccine; Biological: sargramostim |
| 92 | Unknown † | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse | |
| | | Conditions: | Non-Hodgkin's Lymphoma; Follicular Lymphoma; Diffuse Large Cell Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia |
| | | Intervention: | Biological: ISF35 |
| 93 | Suspended | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | |
| | | Conditions: | Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
| | | Interventions: | Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: recombinant interferon alfa; Drug: |
| 94 | Completed | Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer | |
| | | Conditions: | Colorectal Cancer; Metastatic Cancer |
| | | Intervention: | Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine |
| 95 | Unknown † | Immunotherapy in Treating Patients With Metastatic Breast Cancer | |
| | | Condition: | Breast Cancer |
| | | Intervention: | Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine |
| 96 | Recruiting | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | |
| | | Condition: | Adenocarcinoma of the Ovary |
| | | Intervention: | Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine |
| 97 | Recruiting | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | |
| | | Conditions: | Lung Cancer; Adenocarcinoma |
| | | Interventions: | Biological: GM.CD40L.CCL21 Vaccinations; Biological: GM.CD40L cells Vaccinations |
| 98 | Recruiting | A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer | |
| | | Condition: | Metastatic Renal Cell Carcinoma |
| | | Intervention: | Biological: Combig-DC (allogeneic dendritic cells) Cancer Vaccine |
| 99 | Recruiting | Phase 1 Study of ONT-10 in Patients With Solid Tumors | |
| | | Condition: | Solid Tumors |
| | | Intervention: | Biological: ONT-10 |
| 100 | Active, not recruiting | Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 | |
| | | Condition: | NY-ESO-1 Positive, Advanced, Solid Tumors |
| | | Intervention: | Biological: IMF-001 |
| 101 | Active, not recruiting | Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer | |
| | | Conditions: | Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer |
| | | Interventions: | Biological: sipuleucel-T; Drug: abiraterone acetate |
| 102 | Active, not recruiting | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | |
| | | Conditions: | Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma |
| | | Interventions: | Biological: sipuleucel-T; Drug: leuprolide acetate |
| 103 | Completed | Provence® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | |

| | | | |
|-----|-------------------------------|--|--|
| | Has | Condition: | Prostate Cancer |
| | | Interventions: | Biological: Sipuleucel-T; Biological: APC-Placebo |
| 104 | Unknown † | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, | |
| | | Conditions: | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer |
| | | Interventions: | Biological: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine; Biological: tetanus toxoid helper peptide; |
| 105 | Active, not recruiting | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | |
| | | Condition: | Metastatic Renal Cell Carcinoma |
| | | Interventions: | Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide |
| 106 | Unknown † | The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being | |
| | | Condition: | Cervical Cancer |
| | | Intervention: | |
| 107 | Active, not recruiting | Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer | |
| | | Condition: | Prostate Cancer |
| | | Interventions: | Biological: BCG vaccine; Biological: prostate cancer vaccine ONY-P1; Other: placebo |
| 108 | Recruiting | Phase II FANG in Advanced Melanoma | |
| | | Condition: | Advanced Melanoma |
| | | Intervention: | Biological: FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma |
| 109 | Recruiting | L-BLP25 (Stimuvax) in Rectal Cancer | |
| | | Condition: | Rectal Cancer |
| | | Interventions: | Other: Chemoradiation Therapy; Drug: Cyclophosphamide; Biological: L-BLP25 |
| 110 | Recruiting | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | |
| | | Condition: | Cervical Cancer |
| | | Interventions: | Biological: live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001; Other: laboratory biomarker analysis |
| 111 | Not yet recruiting | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small | |
| | | Conditions: | Non-Small Cell Lung Cancer; Non-small-cell Lung Carcinoma; Lung Cancer; NSCLC |
| | | Interventions: | Biological: gp96-Ig Vaccine; Drug: Theophylline; Other: Oxygen; Procedure: Immunologic Evaluation |
| 112 | Recruiting | Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer | |
| | | Condition: | Prostate Cancer |
| | | Interventions: | Biological: AdV-tk + valacyclovir; Biological: Placebo + valacyclovir |
| 113 | Terminated | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube | |
| | | Conditions: | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
| | | Interventions: | Biological: oregovomab; Drug: cyclophosphamide; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: adjuvant therapy |
| 114 | Recruiting | Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and | |
| | | Condition: | Pancreatic Cancer |
| | | Interventions: | Drug: Cyclophosphamide; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine; |
| 115 | Completed | Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | |

| | | | |
|-----|------------------------|--|--|
| | | Conditions: | Colon Cancer; Lung Cancer; Breast Cancer |
| | | Intervention: | Biological: AD5 CEA Vaccine |
| 116 | Completed | Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer | |
| | | Condition: | Pancreatic Cancer |
| | | Interventions: | Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine |
| 117 | Completed | Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma | |
| | | Condition: | Multiple Myeloma |
| | | Intervention: | Biological: Dendritic Cell Tumor Fusion |
| 118 | Active, not recruiting | A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 | |
| | | Conditions: | Prostatic Neoplasms; Prostate Specific Antigens |
| | | Interventions: | Drug: TARP 29-35 Peptide (Native Peptide); Drug: TARP 29-37-9V Peptide Epitope Enhanced Peptide |
| 119 | Recruiting | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | |
| | | Conditions: | Severe Combined Immunodeficiency; Malignancy, Hematologic; Neuroblastoma; Neoplasm; |
| | | Intervention: | Procedure: Venipuncture |
| 120 | Terminated | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | |
| | | Condition: | Ovarian Cancer |
| | | Interventions: | Biological: BCG vaccine; Biological: autologous tumor cell vaccine; Drug: carboplatin; Drug: cisplatin; Drug: |
| 121 | Active, not recruiting | Universal GM-CSF-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | |
| | | Condition: | Lymphoma |
| | | Interventions: | Drug: Cyclophosphamide, Hyperfractionated Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Dexamethasone; Drug: High-Dose Methotrexate; Biological: Autologous Tumor Cell-Based |
| 122 | Active, not recruiting | Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | |
| | | Condition: | Multiple Myeloma |
| | | Interventions: | Biological: Telomerase (hTERT vaccine + pneumococcal conjugate vaccine (PCV)); Biological: PCV vaccine |
| 123 | Recruiting | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of | |
| | | Conditions: | Lung Cancer; Esophageal Cancer; Malignant Pleural Mesothelioma; Thymoma; Thymic Carcinoma |
| | | Interventions: | Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; Drug: cyclophosphamide |
| 124 | Recruiting | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized | |
| | | Conditions: | Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancies |
| | | Intervention: | Biological: Allogenic Tumor Cell Vaccine (K562) |
| 125 | Terminated | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | |
| | | Condition: | Bladder Cancer |
| | | Interventions: | Biological: CDX-1307 Vaccine Regimen; Drug: Chemotherapy |
| 126 | Terminated | Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV | |
| | | Condition: | Non-small-cell Lung Cancer (NSCLC) Stage IIIB/IV |

| | | | |
|-----|-------------------------------|---|--|
| | | Intervention: | Biological: Recombinant Human rEGF-P64K/Montanide Vaccine |
| 127 | Completed | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, | |
| | | Conditions: | Breast Cancer; Colorectal Cancer; Pancreatic Cancer; Bladder Cancer; Ovarian Cancer |
| | | Intervention: | Biological: CDX-1307 |
| 128 | Recruiting | Tumor Cell Vaccines and ISCOMATRIX(Trademark) With Chemotherapy After Tumor Removal | |
| | | Conditions: | Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancy |
| | | Interventions: | Biological: Epigenetically Modified Autologous Tumor; Drug: Cyclophosphamide; Drug: Celecoxib |
| 129 | Withdrawn | Dendritic Cell Based Therapy for Breast Cancer Patients | |
| | | Condition: | Breast Cancer |
| | | Interventions: | Biological: DC vaccine; Drug: aromatase inhibitor |
| 130 | Completed | GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | |
| | | Conditions: | Myelodysplastic Syndrome RAEB-I or RAEB-II; Refractory Acute Myeloid Leukemia; Refractory CML Myeloid |
| | | Intervention: | Biological: GM-CSF secreting leukemia vaccine |
| 131 | Terminated | A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine- | |
| | | Condition: | Breast Cancer |
| | | Interventions: | Biological: Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Biological: Placebo of |
| 132 | Completed | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | |
| | | Condition: | Melanoma |
| | | Interventions: | Biological: NY-ESO-1 ISCOMATRIX® vaccine; Drug: Cyclophosphamide |
| 133 | Completed | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | |
| | | Conditions: | Breast Cancer; Colorectal Cancer; Pancreatic Cancer; Bladder Cancer; Ovarian Cancer |
| | | Intervention: | Biological: CDX1307 |
| 134 | Completed | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | |
| | | Condition: | Melanoma |
| | | Interventions: | Biological: NY-ESO-1 ISCOMATRIX®; Biological: ISCOMATRIX® adjuvant |
| 135 | Active, not recruiting Has | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | |
| | | Condition: | Glioblastoma Multiforme |
| | | Interventions: | Biological: Autologous Dendritic Cell; Drug: Temozolomide; Procedure: Radiotherapy; Biological: Dendritic Cell |
| 136 | Completed | Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 | |
| | | Condition: | Neoplasms |
| | | Intervention: | Biological: protein vaccination |
| 137 | Completed | Dendritic Cell Based Therapy of Malignant Melanoma | |
| | | Condition: | Advanced Melanoma |
| | | Intervention: | Biological: tumor antigen loaded autologous dendritic cells |
| 138 | Completed | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | |
| | | Condition: | Carcinoma, Non-Small-Cell Lung |

| | | | |
|-----|------------------------|---|---|
| | | Intervention: | Biological: MVA-MUC1-IL2 |
| 139 | Completed | A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian | |
| | | Conditions: | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
| | | Interventions: | Biological: NY-ESO-1 OLP4; Biological: NY-ESO-1 OLP4 + Montanide; Biological: NY-ESO-1 OLP4 + Montanide |
| 140 | Recruiting | Sipuleucel-T Manufacturing Demonstration Study | |
| | | Conditions: | Cancer of Prostate; Cancer of the Prostate; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms; Prostatic Cancer |
| | | Intervention: | Biological: sipuleucel-T |
| 141 | Active, not recruiting | Open Label Study of Sipuleucel-T | |
| | | Condition: | Prostate Cancer |
| | | Intervention: | Drug: Sipuleucel-T |
| 142 | Active, not recruiting | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen | |
| | | Condition: | Prostate Cancer |
| | | Intervention: | Biological: Sipuleucel-T |
| 143 | Recruiting | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 | |
| | | Condition: | Prostate Cancer |
| | | Intervention: | Drug: sipuleucel-T |
| 144 | Completed | A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | |
| | | Conditions: | Breast Cancer; Ovarian Cancer; Prostate Cancer; Colon Cancer; Renal Cancer |
| | | Intervention: | Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) |
| 145 | Recruiting | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | |
| | | Condition: | Urothelial Carcinoma |
| | | Interventions: | Biological: DN24-02; Other: Standard of Care |
| 146 | Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | |
| | | Conditions: | Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of |
| | | Intervention: | Biological: PSMA/PRAME |
| 147 | Completed | A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer | |
| | | Conditions: | Metastatic Pancreatic Cancer; Nonresectable Pancreatic Cancer |
| | | Intervention: | Biological: CG 8020 and CG 2505 |
| 148 | Completed | Phase II Trial of Allovectin-7® for Head and Neck Cancer | |
| | | Conditions: | Head and Neck Cancer; Squamous Cell Carcinoma of the Oral Cavity or Oropharynx; Head and Neck Neoplasms; Carcinoma of the Head and Neck |
| | | Intervention: | Genetic: Allovectin-7® |
| 149 | Active, not recruiting | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | |
| | | Condition: | Advanced Malignancies |

| | | | |
|-----|-------------|--|---|
| | | Intervention: | Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC |
| 150 | Completed | Study of Stimuvax in Patients With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | |
| | | Condition: | Multiple Myeloma |
| | | Interventions: | Biological: L-BLP25, cyclophosphamide prior to first vaccination; Biological: L-BLP25 |
| 151 | Completed | IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful | |
| | | Condition: | Colorectal Carcinoma |
| | | Interventions: | Drug: Endoxana, Leukine, IMA910; Drug: Endoxana, Leukine, IMA910, Aldara |
| 152 | Recruiting | Study of a DNA Immunotherapy to Treat Melanoma | |
| | | Condition: | Malignant Melanoma |
| | | Intervention: | Biological: SCIB1 |
| 153 | Completed | Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer | |
| | | Condition: | Gastric Cancer |
| | | Intervention: | Biological: peptide vaccine |
| 154 | Completed | Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer | |
| | | Condition: | Esophageal Cancer |
| | | Intervention: | Biological: URLC10 |
| 155 | Completed | Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic | |
| | | Conditions: | Leukemia; Multiple Myeloma and Plasma Cell Neoplasm |
| | | Interventions: | Biological: autologous tumor cell vaccine; Biological: peripheral blood lymphocyte therapy |
| 156 | Recruiting | Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls | |
| | | Condition: | HPV Infections |
| | | Interventions: | Biological: Cervarix; Biological: Gardasil |
| 157 | Unknown † | Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells | |
| | | Condition: | Carcinoma, Hepatocellular |
| | | Intervention: | Biological: DC vaccine |
| 158 | Unknown † | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | |
| | | Condition: | Melanoma (Skin) |
| | | Interventions: | Biological: BCG vaccine; Biological: autologous tumor cell vaccine; Biological: recombinant interferon alfa; Drug: chemotherapy; Drug: cyclophosphamide |
| 159 | Completed | Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line | |
| | | Condition: | Lung Cancer |
| | | Intervention: | Biological: Ad100-gp96Ig-HLA A1 |
| 160 | Terminated | Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer | |
| | Has | Conditions: | Breast Neoplasms; Metastases, Neoplasm |
| | | Interventions: | Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: recombinant vaccinia-CEA(6D)/TRICOM |
| 161 | Active, not | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | |

| | | | |
|-----|--------------------|--|---|
| | recruiting | Condition: | Malignant Glioma |
| | | Interventions: | Drug: CDX-110 with GM-CSF; Drug: temozolomide |
| 162 | Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic | |
| | | Conditions: | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Stage IV Melanoma; Stage IV Non-small Cell |
| | | Intervention: | Biological: ipilimumab |
| 163 | Completed | Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients | |
| | | Condition: | Breast Neoplasms |
| | | Intervention: | Drug: THERATOPE® vaccine |
| 164 | Unknown † | Novel Adjuvants for Peptide-Based Melanoma Vaccines | |
| | | Condition: | Melanoma |
| | | Intervention: | Biological: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine |
| 165 | Unknown † | Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 | |
| | | Condition: | Leukemia, Myeloid, Acute |
| | | Interventions: | Biological: RFUSIN2-AML1; Biological: Donor leukocyte infusion (DLI); Biological: RFUSIN2-AML1 and donor |
| 166 | Not yet recruiting | Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma | |
| | | Condition: | Lymphoma |
| | | Intervention: | Biological: DNA Vaccine |
| 167 | Recruiting | Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | |
| | | Condition: | Lymphoma, Mantle-Cell |
| | | Interventions: | Biological: CpG-MCL vaccine, primed T-cells; Procedure: Autologous peripheral blood stem cell transplantation; |
| 168 | Completed | An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer | |
| | | Conditions: | Colonic Neoplasms; Colorectal Neoplasms |
| | | Intervention: | Biological: EP2101 |
| 169 | Completed | An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer | |
| | | Conditions: | Carcinoma, Non-Small-Cell Lung; Lung Neoplasm |
| | | Intervention: | Biological: EP2101 |
| 170 | Terminated | TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) | |
| | | Condition: | Hormone Refractory Prostate Cancer |
| | | Interventions: | Drug: Docetaxel; Drug: TroVax + Docetaxel |
| 171 | Completed | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease | |
| | | Condition: | Renal Cell Carcinoma |
| | | Interventions: | Drug: Endoxana, IMA901, Leukine; Drug: IMA901 and Leukine |
| 172 | Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma | |
| | | Condition: | Melanoma (Skin) |
| | | Intervention: | Biological: MKC1106-MT |
| 173 | Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma | |
| | | Condition: | Melanoma (Skin) |

| | | | |
|-----|------------------------|---|---|
| | | Intervention: | Biological: Synchrotope TA2M |
| 174 | Withdrawn | Dendritic Cell Vaccine for Head and Neck Cancer | |
| | | Condition: | Squamous Cell Carcinoma of Head and Neck |
| | | Intervention: | Biological: dendritic cell vaccine |
| 175 | Completed | Collection and Banking of Leukemia Cells MDS/AML | |
| | | Conditions: | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
| | | Intervention: | Other: Collection of Leukemia Cells |
| 176 | Completed | A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma | |
| | | Condition: | Carcinoma |
| | | Intervention: | Drug: LTX-315 |
| 177 | Recruiting | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | |
| | | Condition: | HER2+ Cancer |
| | | Intervention: | Biological: AVX901 |
| 178 | Recruiting | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | |
| | | Conditions: | Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component |
| | | Interventions: | Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH |
| 179 | Unknown † | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | |
| | | Condition: | Prostate Cancer |
| | | Intervention: | Biological: PROSTVAC®-VF/TRICOM™ |
| 180 | Completed | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | |
| | | Condition: | Malignant Melanoma |
| | | Interventions: | Biological: NY-ESO-1 protein; Drug: Imiquimod |
| 181 | Recruiting | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | |
| | | Condition: | Prostate Cancer |
| | | Interventions: | Drug: Flutamide; Biological: Sargramostim; Biological: recombinant fowlpox-prostate apecific antigen vaccine; |
| 182 | Unknown † | Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) | |
| | | Condition: | Cervical Cancer |
| | | Intervention: | Biological: HPV16 E7 peptide-pulsed autologous DCs |
| 183 | Active, not recruiting | A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | |
| | | Conditions: | Sarcoma; Neuroblastoma; Wilm's Tumor |
| | | Interventions: | Biological: tumor lysate-pulsed dendritic cell vaccine; Other: hematopoietic stem cell transplantation (HSCT) |
| 184 | Completed | A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in | |
| | Has | Conditions: | Ewing's Sarcoma; Rhabdomyosarcoma |
| | | Interventions: | Biological: therapeutic autologous dendritic cells; Drug: indinavir sulfate; Procedure: peripheral blood stem cell |
| 185 | Active, not recruiting | Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | |
| | | Condition: | Mantle Cell Lymphoma |
| | | Interventions: | Drug: Rituximab; Drug: autologous tumor cell vaccine; Drug: doxorubicin; Drug: cyclophosphamide; Drug: |

| | | |
|-----|------------------------|---|
| 186 | Completed | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
| | | Condition: Carcinoma, Non-Small-Cell Lung |
| | | Intervention: Drug: Hyperacute Lung Cancer Cell Vaccine |
| 187 | Completed | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric |
| | | Conditions: Ewing's Sarcoma; Rhabdomyosarcoma |
| | | Interventions: Drug: EF-1 Peptide; Drug: EF-2 Peptide; Drug: PXXK Peptide; Drug: E7 Peptide; Drug: IL-2; Drug: IL-4; |
| 188 | Completed | Dendritic Cells in Lung Cancer |
| | | Condition: Non Small Cell Lung Cancer |
| | | Intervention: Biological: Allogeneic Tumour Lysate (MelCancerVac) |
| 189 | Completed Has | Sequential Vaccinations in Prostate Cancer Patients |
| | | Condition: Prostatic Neoplasms |
| | | Interventions: Drug: Recombinant Fowlpox-GM-CSF; Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC- |
| 190 | Completed | Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2 |
| | | Condition: Breast Neoplasms |
| | | Intervention: Biological: CD34+ derived DCs |
| 191 | Active, not recruiting | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) |
| | | Conditions: Pancreatic Adenocarcinoma; Pancreatic Cancer |
| | | Interventions: Biological: AdV-tk; Drug: Valacyclovir |
| 192 | Recruiting | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer |
| | | Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor |
| | | Intervention: Drug: Dendritic cell immunotherapy |
| 193 | Active, not recruiting | Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) |
| | | Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma |
| | | Interventions: Biological: AdV-tk; Drug: Valacyclovir |
| 194 | Active, not recruiting | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas |
| | | Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma |
| | | Interventions: Biological: AdV-tk; Drug: Valacyclovir |
| 195 | Recruiting | Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials |
| | | Condition: Non-Hodgkin's Lymphoma |
| | | Intervention: Procedure: Procurement of Follicular B Cell Lymphoma Cells |
| 196 | Recruiting | A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine |
| | | Condition: Pancreatic Cancer |
| | | Intervention: Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine. |
| 197 | Active, not recruiting | Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2 |
| | | Condition: Breast Cancer |
| | | Interventions: Biological: HER-2/neu intracellular domain protein; Other: flow cytometry; Other: immunohistochemistry staining |
| 198 | Recruiting | Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma |
| | | Condition: Malignant Glioma |
| | | Intervention: Biological: Dendritic Cell Vaccine in combination with Imiquimod cream |
| 199 | Completed | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers |

| | | | |
|-----|------------------------|---|---|
| | | Conditions: | Esophageal Cancer; Lung Cancer; Stomach Cancer; Breast Cancer; Ovarian Cancer |
| | | Intervention: | Drug: CHP-HER2, CHP-NY-ESO-1 |
| 200 | Recruiting | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | |
| | | Condition: | Multiple Myeloma |
| | | Interventions: | Drug: CT-011; Biological: Dendritic Cell Fusion Vaccine |
| 201 | Recruiting | Biology Studies of Hematologic Cancers | |
| | | Condition: | Hematologic Malignancy |
| | | Intervention: | |
| 202 | Recruiting | A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma | |
| | | Conditions: | Malignant; Pleural; Mesothelioma |
| | | Interventions: | Biological: TroVax®; Drug: Pemetrexed; Drug: Cisplatin; Dietary Supplement: Vitamin B12; Dietary |
| 203 | Terminated | Vaccination With Tetanus and KLH to Assess Immune Responses. | |
| | | Condition: | Cancer |
| | | Interventions: | Biological: Intracel KLH Vaccine; Biological: Biosyn KLH; Drug: Montanide ISA51; Biological: Tetanus toxoid |
| 204 | Unknown † | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | |
| | | Condition: | Metastatic Melanoma |
| | | Intervention: | Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod. |
| 205 | Completed | Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients | |
| | | Condition: | Malignant Glioma |
| | | Intervention: | Biological: Dendritic cell Vaccine |
| 206 | Active, not recruiting | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | |
| | | Condition: | Metastatic Melanoma |
| | | Interventions: | Biological: Vaccination; Procedure: Leukapheresis |
| 207 | Completed | Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer | |
| | Has | Condition: | Lung Cancer |
| | | Interventions: | Biological: Vaccine Treatment; Drug: Cyclophosphamide; Drug: All-trans retinoic acid (ATRA) |
| 208 | Terminated | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From | |
| | | Conditions: | Primary Advanced Carcinoma of the Oral Cavity or Oropharynx; Squamous Cell Carcinoma of the Head and Neck |
| | | Intervention: | Biological: autologous monocyte-derived dendritic cells (DC) transfected with DNA |
| 209 | Active, not recruiting | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | |
| | | Conditions: | Astrocytoma; Oligoastrocytoma; Oligodendroglioma |
| | | Intervention: | Biological: Peptide vaccine + Poly-ICLC |
| 210 | Active, not recruiting | Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO | |
| | | Conditions: | Astrocytoma; Oligo-Astrocytoma; Glioma |
| | | Intervention: | Biological: GAA/TT-peptide vaccine and poly-ICLC |
| 211 | Recruiting | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | |
| | | Condition: | Follicular Lymphoma |